TRAF3Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma

MLA

Li, Michael Y., et al. “TRAF3Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma.” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 2042–43. EBSCOhost, https://doi.org/10.1182/blood-2022-159679.

APA

Li, M. Y., Chong, L. C., Woolcock, B. W., Telenius, A., Ben-Neriah, S., Slack, G. W., Lam, V., Jiang, A., Viganò, E., Aoki, T., Healy, S., Krystal, G., Venturutti, L., Scott, D. W., & Steidl, C. (2022). TRAF3Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma. Blood, 140(1, Number 1 Supplement 1), 2042–2043. https://doi.org/10.1182/blood-2022-159679

Chicago

Li, Michael Y., Lauren C. Chong, Bruce W Woolcock, Adèle Telenius, Susana Ben-Neriah, Graham W Slack, Vivian Lam, et al. 2022. “TRAF3Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma.” Blood 140 (1, Number 1 Supplement 1): 2042–43. doi:10.1182/blood-2022-159679.